AA4500: Phase III halted

By WIR Staff | Dec 11, 2006 | 8:00 AM GMT

AUXL temporarily suspended dosing in a double-blind, placebo-controlled, Australian and Swiss Phase III trial of AA4500 to treat Dupuytren's